Table 2. Data for BsAb in treating R/R... | American Society of Hematology

Table 2.

Data for BsAb in treating R/R MCL

Agent’	N	Activity
Epcoritamab¹⁸	4	One patient with CR, 1 PR, and 1 stable disease. Both responses occurred in patients with blastoid or pleomorphic MCL.
Glofitamab²¹^,²²	29	ORR 85%, CR 78.3%; mDOR 16.2 mo, mDOCR 15.4 mo
Mosunetuzumab + polatuzumab-vedotin²³^,²⁴	20	ORR 75%, CRR 70%; mDOCR NR
Odronextamab²⁵	12	ORR 50%, CRR 33%; mDOR 10.9 mo

Agent’	N	Activity
Epcoritamab¹⁸	4	One patient with CR, 1 PR, and 1 stable disease. Both responses occurred in patients with blastoid or pleomorphic MCL.
Glofitamab²¹^,²²	29	ORR 85%, CR 78.3%; mDOR 16.2 mo, mDOCR 15.4 mo
Mosunetuzumab + polatuzumab-vedotin²³^,²⁴	20	ORR 75%, CRR 70%; mDOCR NR
Odronextamab²⁵	12	ORR 50%, CRR 33%; mDOR 10.9 mo

CRR, complete response rate; NR, not reached.